Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms
NCT ID: NCT07272681
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-12-20
2026-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
H. pylori-positive adults - Eradication therapy group - Adult patients with H. pylori infection
Adult patients with confirmed Helicobacter pylori infection who have received standard eradication therapy prescribed by their healthcare providers. The study will observe and evaluate changes in gastrointestinal symptoms after completion of the prescribed treatment, without altering or influencing the treatment regimen.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.
3. Presence of any upper or lower gastrointestinal symptoms.
4. Willingness to undergo H. Pylori eradication therapy and follow-up.
5. Ability to provide informed consent.
Exclusion Criteria
2. The previously unsuccessful application of empirical H. pylori eradication therapy.
3. Use of non-steroidal anti-inflammatory drugs (NSAIDs).
4. Any malignant disease of the stomach or any other site.
5. Any associated comorbidity (renal insufficiency, mental illness).
6. History of allergies to proton pump inhibitors or antibiotics.
7. Refusal to participate in the survey.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amany Usama Ahmed Arafa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amany Usama Ahmed Arafa
Resident doctor, Tropical Medicine and Gastroenterology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amany Usama
Role: PRINCIPAL_INVESTIGATOR
Department of Gastroenterology and Tropical medicine Sohag University Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med--25-11-1MS
Identifier Type: -
Identifier Source: org_study_id